Latest Conference Coverage


Krystyn J. Van Vliet, PhD & Anna Jagielska, PhD, MSc

Bridging Engineering and Neuroscience in the Creation of Artificial Axons for Myelination Research: Krystyn J. Van Vliet, PhD & Anna Jagielska, PhD, MSc

April 11th 2024

The professor of materials science and engineering at Cornell University and chief executive officer at Artificial Axon Labs talked about the development of artificial axons through 3D printing. [WATCH TIME: 6 minutes]


Shiv Saidha, MBBCh

Reevaluating Neuroprotective Multiple Sclerosis Trial Designs Using the Visual System: Shiv Saidha, MBBCh

April 8th 2024

The professor of neurology at Johns Hopkins Medicine discussed the trial design of the phase 4 RENEW study assessing the long-term safety profile of mitoxantrone in multiple sclerosis. [WATCH TIME: 9 minutes]


Marjan Gharagozloo, PhD

The Potential of NLRX1 in Immune Regulation and Neuroprotection for Inflammatory Neurodegenerative Disorders: Marjan Gharagozloo, PhD

April 7th 2024

The assistant professor of neurology at Johns Hopkins Medicine talked about her preclinical research in immunology to explore the intricate mechanisms controlling chronic inflammation in the central nervous system. [WATCH TIME: 5 minutes]


Marcello Paglione, PhD

Givinostat's Multifactorial Mechanism of Action in Duchenne Muscular Dystrophy: Marcello Paglione, PhD

April 5th 2024

The executive medical lead at Italfarmaco SpA expressed his confidence in givinostat to mitigate the progression of Duchenne muscular dystrophy, emphasizing its multifactorial mechanism of action. [WATCH TIME: 5 minutes]


Shiv Saidha, MBBCh

Targeting Neurodegeneration to Impart Neuroprotection in Progressive MS: Shiv Saidha, MBBCh

April 4th 2024

The professor of neurology at Johns Hopkins Medicine discussed the limited impact of current therapies on retinal atrophy rates in progressive multiple sclerosis at the 2024 ACTRIMS Forum. [WATCH TIME: 5 minutes]


Marcello Paglione, PhD

Evaluating Givinostat's Efficacy and Safety in Duchenne Muscular Dystrophy: Marcello Paglione, PhD

April 3rd 2024

The executive medical lead at Italfarmaco SpA talked about data from both animal models and clinical trials supporting the efficacity of givinostat in patients with Duchenne muscular dystrophy at MDA 2024. [WATCH TIME: 5 minutes]


Aki Ko, chief executive officer at Elixirgen Therapeutics

Elixirgen Therapeutics’ Bobcat mRNA Therapeutic for Duchenne Muscular Dystrophy: Aki Ko

March 28th 2024

The chief executive officer at Elixirgen Therapeutics discussed the company’s mRNA as a promising therapeutic avenue for Duchenne muscular dystrophy. [WATCH TIME: 6 minutes]


Le Hua, MD

Analyzing Cognitive Profiles in Multiple Sclerosis and Alzheimer Disease: Le Hua, MD

March 27th 2024

The director of the Multiple Sclerosis Program at the Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed findings from a study that compared cognitive profiles between patients with multiple sclerosis and Alzheimer disease. [WATCH TIME: 5 minutes]


Amanda Peltier, MD

Integrating Genetics and Transitional Support in Muscular Dystrophy Care: Amanda Peltier, MD

March 27th 2024

The professor of neurology at Vanderbilt University Medical Center discussed advocating for reinstating personalized resources, expanding genetic testing, and improving transitional care in muscular dystrophy. [WATCH TIME: 5 minutes]


Promising Preclinical Evidence of Skeletal Muscle Regenerator SAT-3247: Frank Gleeson

Promising Preclinical Evidence of Skeletal Muscle Regenerator SAT-3247: Frank Gleeson

March 26th 2024

The president and chief executive officer of Satellos Bioscience provided an overview of the previously observed preclinical data supporting SAT-3247 as a potential therapy for muscular dystrophies. [WATCH TIME: 4 minutes]


Justin Moy

A Patient Perspective on Gene Therapy for Neuromuscular Diseases: Justin Moy

March 26th 2024

The second-year PhD student in bioinformatics at Boston University who lives with LAMA2 congenital muscular dystrophy talked about the potential impact and challenges of gene therapy in neuromuscular diseases. [WATCH TIME: 5 minutes]


Amanda Peltier, MD

Enhancing Multidisciplinary Care for Neuromuscular Disorders: Amanda Peltier, MD

March 25th 2024

The professor of neurology at Vanderbilt University Medical Center talked about the importance of multidisciplinary care centers to improve accessibility and quality of care for patients with neuromuscular disorders. [WATCH TIME: 5 minutes]


Marjan Gharagozloo, PhD

Targeting the NLRX1 Pathway for Neuroprotection in Multiple Sclerosis: Marjan Gharagozloo, PhD

March 25th 2024

The assistant professor of neurology at Johns Hopkins Medicine talked about recent research that suggests activating the NLRX1 pathway could offer neuroprotection in multiple sclerosis. [WATCH TIME: 5 minutes]


 Jeffrey Huang, PhD

Therapeutic Avenues for Multiple Sclerosis Through Immune Cell Communication: Jeffrey Huang, PhD

March 24th 2024

The associate professor of biology at Georgetown University talked about how immune cells can communicate with brain cells to enhance repair processes, which may offer potential treatment targets for multiple sclerosis. [WATCH TIME: 5 minutes]


Clinical Benefits to Emphasizing Patient Voices in ALS: Brooke Eby

Clinical Benefits to Emphasizing Patient Voices in ALS: Brooke Eby

March 22nd 2024

A patient advocate within the ALS community discussed the importance of incorporating patients and their voices into clinical meetings and trial design to ultimately meet treatment goals. [WATCH TIME: 4 minutes]


Overviewing Phase 2 SYNAPSE-SMA Trial of NMD670 for Spinal Muscular Atrophy: Jorge Quiroz, MD, MBA

Overviewing Phase 2 SYNAPSE-SMA Trial of NMD670 for Spinal Muscular Atrophy: Jorge Quiroz, MD, MBA

March 22nd 2024

The chief medical officer of NMD Pharma provided perspective on a newly launched phase 2 study assessing NMD670, a first-in-class neuromuscular transmission enhancer, in patients with spinal muscular atrophy type 3. [WATCH TIME: 5 minutes]


Episode 111: Reviewing ACTRIMS 2024

Episode 111: Reviewing ACTRIMS 2024

March 22nd 2024

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 32 minutes]


Shiv Saidha, MBBCh

Clinical Significance of Visual System Modeling for Multiple Sclerosis Research: Shiv Saidha, MBBCh

March 21st 2024

The professor of neurology at Johns Hopkins Medicine talked about modeling visual systems as an area of focus in clinical trials for multiple sclerosis as it may offer insights into neurodegeneration and neuroprotection. [WATCH TIME: 6 minutes]


Julie Fiol, MSCN; Andreina Barnola, MD, MPH

Desert Mapping to Promote Health Equity in Multiple Sclerosis Care: Julie Fiol, MSCN; Andreina Barnola, MD, MPH

March 21st 2024

The associate vice president of clinical Innovation and strategy and the health equity director at National MS Society talked about leveraging data mapping to bridge healthcare gaps and promote health equity in multiple sclerosis. [WATCH TIME: 4 minutes]


Flaws in Assessment Scales for Neuromuscular Conditions: Laurent Servais, MD, PhD

Flaws in Assessment Scales for Neuromuscular Conditions: Laurent Servais, MD, PhD

March 20th 2024

The professor of pediatric neuromuscular diseases at the University of Oxford provided commentary on the commonly used scales to assess neuromuscular function and where inconsistencies have been observed. [WATCH TIME: 7 minutes]


NeuroVoices: Aki Ko, on mRNA Therapeutics for Duchenne Muscular Dystrophy

NeuroVoices: Aki Ko, on mRNA Therapeutics for Duchenne Muscular Dystrophy

March 20th 2024

The chief executive officer at Elixirgen Therapeutics provided commentary on the promise of the Bobcat mRNA, and the mechanism of action for mRNA-like therapies to treat Duchenne muscular dystrophy.


Lars Alfredsson, PhD

Association Between Obesity and Disease Progression in Multiple Sclerosis: Lars Alfredsson, PhD

March 19th 2024

The professor of epidemiology at Karolinska Institutet talked about findings from a comprehensive study on the correlation between obesity and accelerated progression of multiple sclerosis. [WATCH TIME: 8 minutes]


Jenn Orthmann-Murphy, MD, PhD

Advancing Neural Repair Through Cellular Responses and Biomarkers in MS Models: Jenn Orthmann-Murphy, MD, PhD

March 18th 2024

The assistant professor of neurology in the Perelman School of Medicine at University of Pennsylvania discussed preclinical research on neural repair in multiple sclerosis at ACTRIMS Forum 2024. [WATCH TIME: 4 minutes]


Improving MS Care Through Innovative Trial Designs: Daniel Ontaneda, MD, PhD

Improving MS Care Through Innovative Trial Designs: Daniel Ontaneda, MD, PhD

March 18th 2024

Following the 2024 ACTRIMS Forum, the associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided insight on the need to build creative trials for multiple sclerosis treatments. [WATCH TIME: 3 minutes]


Amit Bar-Or, MD, FRCPC, FAAN, FANA

Exploring the Potential Therapeutic Avenue of BTK Inhibitors for Progressive MS: Amit Bar-Or, MD, FRCPC, FAAN, FANA

March 17th 2024

The Melissa and Paul Anderson President’s Distinguished Professor of Neurology, Perelman School of Medicine, University of Pennsylvania, discussed the promising avenue of BTK inhibitors for addressing progressive multiple sclerosis. [WATCH TIME: 5 minutes]


Dimitrios Karussis, MD, PhD

Repeated Intrathecal Injection of NeuroGenesis’ Mesenchymal Stem Cell Therapy Reveals Potential Benefit in Progressive MS

March 16th 2024

A recent analysis of a phase 2 trial showed that repeated intrathecal injections of MSC therapy led to significant reductions in serum biomarkers and improvements in neurological function for progressive MS.


Jason Freeman, MD, MBA

Consistent Real-World Efficacy of Ofatumumab Therapy for Multiple Sclerosis: Jason Freeman, MD, MBA

March 15th 2024

The medial director of Novartis talked about findings from a real-world study assessing ofatumumab treatment for multiple sclerosis presented at the 2024 ACTRIMS Forum. [WATCH TIME: 3 minutes]

© 2024 MJH Life Sciences

All rights reserved.